Takayama, Tadatoshi

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 1,120

Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

Totoki, Y., Tatsuno, K., Covington, K. R., Ueda, H., Creighton, C. J., Kato, M., Tsuji, S., Donehower, L. A., Slagle, B. L., Nakamura, H., et al. (2014) · Nature Genetics

Cancer Genomics and DiagnosticsHepatocellular Carcinoma Treatment and Prognosis

Cited by 781

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

Pinyol, R., Montal, R., Bassaganyas, L., Sia, D., Takayama, T., Chau, G.-Y., Mazzaferro, V., Roayaie, S., Lee, H. C., Kokudo, N., et al. (2019) · Gut

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 326

Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

Sawada, Y., Yoshikawa, T., Nobuoka, D., Shirakawa, H., Kuronuma, T., Motomura, Y., Mizuno, S., Ishii, H., Nakachi, K., Konishi, M., et al. (2012) · Clinical Cancer Research

Immunotherapy and Immune ResponsesHepatocellular Carcinoma Treatment and Prognosis

Cited by 302

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer ( KHBO1401 ‐ MITSUBA )

Ioka, T., Kanai, M., Kobayashi, S., Sakai, D., Eguchi, H., Baba, H., Seo, S., Taketomi, A., Takayama, T., Yamaue, H., et al. (2023) · Journal of Hepato-Biliary-Pancreatic Sciences

Cholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct Disorders

Cited by 249

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients

Sawada, Y., Yoshikawa, T., Ofuji, K., Yoshimura, M., Tsuchiya, N., Takahashi, M., Nobuoka, D., Gotohda, N., Takahashi, S., Kato, Y., et al. (2016) · OncoImmunology

Hepatocellular Carcinoma Treatment and PrognosisImmunotherapy and Immune Responses

Cited by 178

Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)

Kudo, M., Izumi, N., Kokudo, N., Sakamoto, M., Shiina, S., Takayama, T., Tateishi, R., Nakashima, O., Murakami, T., Matsuyama, Y., et al. (2022) · Hepatology Research

Hepatocellular Carcinoma Treatment and PrognosisHepatitis B Virus Studies

Cited by 83